{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Blood+Coagulation+Disorders&page=34",
    "query": {
      "condition": "Blood Coagulation Disorders",
      "page": 34
    },
    "page_size": 10
  },
  "pagination": {
    "page": 34,
    "page_size": 10,
    "total_count": 884,
    "total_pages": 89,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Blood+Coagulation+Disorders&page=35&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Blood+Coagulation+Disorders&page=33&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T02:05:26.652Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02179359",
      "title": "Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sickle Cell Disease",
        "Transfusion Dependent Alpha- or Beta- Thalassemia",
        "Diamond Blackfan Anemia",
        "Paroxysmal Nocturnal Hemoglobinuria",
        "Glanzmann Thrombasthenia",
        "Severe Congenital Neutropenia",
        "Shwachman-Diamond Syndrome",
        "Non-Malignant Hematologic Disorders"
      ],
      "interventions": [
        {
          "name": "Reduced Toxicity Ablative Regimen",
          "type": "DRUG"
        },
        {
          "name": "Reduced Intensity Preparative Regimen",
          "type": "DRUG"
        },
        {
          "name": "Myeloablative Preparative Regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "Up to 55 Years"
      },
      "enrollment_count": 38,
      "start_date": "2014-09-02",
      "completion_date": "2024-11-21",
      "has_results": false,
      "last_update_posted_date": "2025-03-03",
      "last_synced_at": "2026-10-16T02:05:26.652Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02179359"
    },
    {
      "nct_id": "NCT05904210",
      "title": "Retrospective Experience Assessing the Real-World Utilization and Effectiveness of SEVENFACT®",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hemophilia"
      ],
      "interventions": [
        {
          "name": "SEVENFACT®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Laboratoire français de Fractionnement et de Biotechnologies",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 17,
      "start_date": "2023-11-07",
      "completion_date": "2024-05-09",
      "has_results": false,
      "last_update_posted_date": "2024-06-25",
      "last_synced_at": "2026-10-16T02:05:26.652Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Madera, California • Atlanta, Georgia + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Madera",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Syracuse",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05904210"
    },
    {
      "nct_id": "NCT01520220",
      "title": "Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myeloproliferative Neoplasms of",
        "Polycythemia Vera",
        "Essential Thrombocythemia",
        "Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "LY2784544",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2012-06-11",
      "completion_date": "2017-02-24",
      "has_results": false,
      "last_update_posted_date": "2017-04-12",
      "last_synced_at": "2026-10-16T02:05:26.652Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01520220"
    },
    {
      "nct_id": "NCT01496274",
      "title": "A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia B"
      ],
      "interventions": [
        {
          "name": "rIX-FP",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "CSL Behring",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "12 Years to 65 Years · Male only"
      },
      "enrollment_count": 63,
      "start_date": "2012-02",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2016-05-09",
      "last_synced_at": "2026-10-16T02:05:26.652Z",
      "location_count": 4,
      "location_summary": "Chicago, Illinois • Indianapolis, Indiana • Philadelphia, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01496274"
    },
    {
      "nct_id": "NCT00111215",
      "title": "Treatment and Management of Women With Bleeding Disorders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Menorrhagia",
        "Blood Coagulation Disorders",
        "Blood Platelet Disorders",
        "Von Willebrand Disease",
        "Hematologic Disease"
      ],
      "interventions": [
        {
          "name": "Tranexamic Acid",
          "type": "DRUG"
        },
        {
          "name": "Desmopressin Acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Centers for Disease Control and Prevention",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 100,
      "start_date": "2001-01",
      "completion_date": "2006-09",
      "has_results": false,
      "last_update_posted_date": "2007-03-13",
      "last_synced_at": "2026-10-16T02:05:26.652Z",
      "location_count": 6,
      "location_summary": "Atlanta, Georgia • East Lansing, Michigan • Rochester, Minnesota + 3 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "East Lansing",
          "state": "Michigan"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00111215"
    },
    {
      "nct_id": "NCT03369444",
      "title": "A Factor IX Gene Therapy Study (FIX-GT)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hemophilia B"
      ],
      "interventions": [
        {
          "name": "FLT180a",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University College, London",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 10,
      "start_date": "2017-12-05",
      "completion_date": "2020-10-20",
      "has_results": true,
      "last_update_posted_date": "2022-12-02",
      "last_synced_at": "2026-10-16T02:05:26.652Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03369444"
    },
    {
      "nct_id": "NCT00868309",
      "title": "A Comparison of Crotalinae Equine Immune F(ab)2 Antivenom (Anavip) and Crotalidae Polyvalent Immune Fab,",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Snake Bite",
        "Blood Coagulation Disorders"
      ],
      "interventions": [
        {
          "name": "Anavip",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CroFab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Instituto Bioclon S.A. de C.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 12,
      "start_date": "2005-01",
      "completion_date": "2007-02",
      "has_results": true,
      "last_update_posted_date": "2016-04-18",
      "last_synced_at": "2026-10-16T02:05:26.652Z",
      "location_count": 1,
      "location_summary": "Tucson, Arizona",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00868309"
    },
    {
      "nct_id": "NCT04676048",
      "title": "ASC618 Gene Therapy in Hemophilia A Patients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "ASC618",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ASC Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 12,
      "start_date": "2022-08-03",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2023-02-01",
      "last_synced_at": "2026-10-16T02:05:26.652Z",
      "location_count": 1,
      "location_summary": "Little Rock, Arkansas",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04676048"
    },
    {
      "nct_id": "NCT07115004",
      "title": "Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Von Willebrand Disease (VWD)"
      ],
      "interventions": [
        {
          "name": "VGA039",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vega Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "12 Years to 75 Years"
      },
      "enrollment_count": 60,
      "start_date": "2025-10-15",
      "completion_date": "2028-10",
      "has_results": false,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-10-16T02:05:26.652Z",
      "location_count": 14,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 10 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07115004"
    },
    {
      "nct_id": "NCT00514982",
      "title": "Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hermanski-Pudlak Syndrome",
        "Colitis",
        "Cytokines",
        "Lymphocytes",
        "Drug Evaluation"
      ],
      "interventions": [
        {
          "name": "Mesalamine",
          "type": "DRUG"
        },
        {
          "name": "Infliximab",
          "type": "DRUG"
        },
        {
          "name": "Corticosteroids",
          "type": "DRUG"
        },
        {
          "name": "6-Mercaptopurine",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Adalimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2007-08-07",
      "completion_date": "2011-03-08",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-10-16T02:05:26.652Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00514982"
    }
  ]
}